Personalizing Your
Cancer Journey
Precision Diagnostics
Who We Are
Qualisure Diagnostics Inc. develops molecular tests that enhance cancer care by identifying features that help oncologists personalize treatment.
Understanding which cancers are indolent or aggressive, and which ones are more likely to respond to certain treatments can guide treatment strategy.
Through innovation and collaboration, we help clinicians decide on the right treatment to provide personalized cancer care to every patient.
Introducing Thyroid GuidePx®
Helping guide your papillary thyroid cancer treatment journey!
Latest News
The Technological Drivers Powering Precision Oncology
Previously, we talked about some of the factors that will enhance the adoption of precision oncology. But at its core, precision oncology utilizes a powerful toolbox of technologies that have fundamentally
Unique Thyroid Cancer Tests: New Hope Unveiled
Exciting Development in Thyroid Cancer Treatment: The Clinical Trial Vanguard Features Executive Interview on Innovative Thyroid Cancer Tests. Special thanks to Moe Alsumidaie and The Clinical Trial Vanguard for sharing
Understanding Radioactive Iodine Resistance in Thyroid Cancer: Overcoming Treatment Challenges
Understanding Radioactive Iodine Resistance in Thyroid Cancer: Overcoming Treatment Challenges Radioactive iodine (RAI) therapy is a common and effective treatment for thyroid cancer. However, in some cases, patients may not
Radioactive Iodine Therapy: A Precision Weapon against Thyroid Cancer
Radioactive Iodine Therapy: A Precision Weapon against Thyroid Cancer Radioactive iodine (RAI) is a special treatment for thyroid cancer that uses iodine to destroy cancer cells. It is mostly used
Radiofrequency Ablation: An Alternative Approach to Treating Papillary Thyroid Cancer
Radiofrequency Ablation: An Alternative Approach to Treating Papillary Thyroid Cancer Papillary thyroid cancer (PTC) is the most common type of thyroid cancer, and while surgery remains the primary treatment option,
A clinically useful and biologically informative genomic classifier for papillary thyroid cancer [2023]
Front. Endocrinol., 12 September 2023Sec. Thyroid EndocrinologyVolume 14 – 2023 Clinical management of papillary thyroid cancer depends on estimations of prognosis. Standard care, which relies on prognostication based on clinicopathologic
